Adenovirus, EBV) resistant to pharmacological therapies., Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV
Conditions
Brief summary
Adverse events: To collect any adverse event defined as any significant alteration of vital signs and / or organ function, expressed in clinical, hematochemical and radiological findings according to version 5 of the Common Terminology Criteria for Adverse Events (CTCAE)
Detailed description
Organ damage; overall survival; specific cell viral immunity; variation of viremia.
Interventions
None listed
Sponsors
IRCCS Istituto Giannina Gaslini
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events: To collect any adverse event defined as any significant alteration of vital signs and / or organ function, expressed in clinical, hematochemical and radiological findings according to version 5 of the Common Terminology Criteria for Adverse Events (CTCAE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Organ damage; overall survival; specific cell viral immunity; variation of viremia. | — |
Countries
Italy
Outcome results
None listed